Mersana Therapeutics Dividende
Zukünftiges Wachstum Kriterienprüfungen 0/6
Mersana Therapeutics does not have a record of paying a dividend.
Wichtige Informationen
n/a
Dividendenausschüttung
-2.8%
Rückkaufsrendite
| Gesamte Aktionärsrendite | -2.8% |
| Zukünftige Dividendenrendite | 0% |
| Wachstum der Dividende | n/a |
| Nächster Dividendenzahlungstermin | n/a |
| Ex-Dividendendatum | n/a |
| Dividende pro Aktie | n/a |
| Ausschüttungsquote | n/a |
Aktuelle Dividendenentwicklung
Keine Aktualisierungen
Recent updates
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Fly 29% But Investors Aren't Buying For Growth
Oct 03
Things Look Grim For Mersana Therapeutics, Inc. (NASDAQ:MRSN) After Today's Downgrade
Aug 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 32%
Aug 13Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) 25% Dip In Price Shows Sentiment Is Matching Revenues
Jun 19Mersana Therapeutics: On Hold While Waiting For Any Positive News
May 15Investors Don't See Light At End Of Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Tunnel And Push Stock Down 33%
Apr 25Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Shares Bounce 26% But Its Business Still Trails The Industry
Feb 27Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
Jan 11Here's Why Mersana Therapeutics (NASDAQ:MRSN) Can Manage Its Debt Despite Losing Money
Oct 14Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Jun 09Mersana Therapeutics, Inc.'s (NASDAQ:MRSN) Intrinsic Value Is Potentially 22% Below Its Share Price
Feb 22Mersana gains as FDA grants fast track status for breast cancer drug
Sep 12Mersana Therapeutics: Savvy Partnering But Further Progress Is Needed
Aug 15Taking The Measure Of Mersana Therapeutics
Jan 10Mersana: ADC Developer With New INDs, Sufficient Cash, And XMT-1536 Progress
Jun 29It's Unlikely That The CEO Of Mersana Therapeutics, Inc. (NASDAQ:MRSN) Will See A Huge Pay Rise This Year
Jun 05Mersana Therapeutics EPS misses by $0.11, misses on revenue
May 10Is Mersana Therapeutics (NASDAQ:MRSN) A Risky Investment?
Mar 23Did Mersana Therapeutics, Inc. (NASDAQ:MRSN) Insiders Buy Up More Shares?
Jan 29
Bain Capital discloses 4.8% stake in Mersana Therapeutics
Jan 13Mersana: XMT-1536's Complications, New CMO, And 2H 2021's Critical Catalyst
Jan 11Stabilität und Wachstum des Zahlungsverkehrs
Rufe Dividendendaten ab
Stabile Dividende: Insufficient data to determine if MRSN's dividends per share have been stable in the past.
Wachsende Dividende: Insufficient data to determine if MRSN's dividend payments have been increasing.
Dividendenrendite im Vergleich zum Markt
| Mersana Therapeutics Dividendenrendite im Vergleich zum Markt |
|---|
| Segment | Dividendenrendite |
|---|---|
| Unternehmen (MRSN) | n/a |
| Untere 25 % des Marktes (US) | 1.5% |
| Markt Top 25 % (US) | 4.5% |
| Branchendurchschnitt (Biotechs) | 2.2% |
| Analystenprognose (MRSN) (bis zu 3 Jahre) | 0% |
Bemerkenswerte Dividende: Unable to evaluate MRSN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Hohe Dividende: Unable to evaluate MRSN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Gewinnausschüttung an die Aktionäre
Abdeckung der Erträge: Insufficient data to calculate MRSN's payout ratio to determine if its dividend payments are covered by earnings.
Barausschüttung an die Aktionäre
Cashflow-Deckung: Unable to calculate sustainability of dividends as MRSN has not reported any payouts.